雅各臣(02633.HK)推流感及呼吸道合胞病毒家用式診斷套件
雅各臣科研製藥(02633.HK)公布,自今年1月起,公司全資附屬雅各臣藥業(香港)已於香港及澳門市場透過不同非處方藥渠道(包括各大保健護理連鎖店及藥房),以「Dr.Freeman醫臣流感/呼吸道合胞病毒快速測試」產品品牌,推出其首個流感及呼吸道合胞病毒(RSV)家用式診斷套件。
該產品是一項簡便的快速家用式檢測工具,專為特定甲型、乙型流感病毒及呼吸道合胞病毒之檢測而設,檢測結果可於8分鐘內得知。該產品使用針對流感及RSV相應抗原的單克隆抗體,除可檢定是否有感染流感外,亦可判斷感染的特定流感及RSV類型。該產品可協助臨床醫生迅速對患者進行針對性抗病毒治療,並制定有效的感染控制措施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.